Headlines about Miragen Therapeutics (NASDAQ:MGEN) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Miragen Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 44.7928951756885 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern’s scoring:

Shares of Miragen Therapeutics (NASDAQ MGEN) traded up $0.02 during mid-day trading on Friday, reaching $5.61. 253,049 shares of the company traded hands, compared to its average volume of 316,830. The stock has a market capitalization of $161.48, a price-to-earnings ratio of 37.40 and a beta of 1.43. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.04. Miragen Therapeutics has a 12 month low of $5.01 and a 12 month high of $18.00.

MGEN has been the topic of a number of research reports. Zacks Investment Research lowered shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Cann reissued a “buy” rating and set a $13.00 price objective on shares of Miragen Therapeutics in a report on Friday, February 2nd. Wedbush reissued a “buy” rating and set a $19.00 price objective on shares of Miragen Therapeutics in a report on Friday, December 1st. Oppenheimer initiated coverage on shares of Miragen Therapeutics in a report on Friday, January 12th. They set an “outperform” rating and a $13.00 price objective on the stock. Finally, Chardan Capital reissued a “buy” rating on shares of Miragen Therapeutics in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $16.46.

In related news, Director Thomas E. Hughes sold 12,000 shares of Miragen Therapeutics stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $8.00, for a total transaction of $96,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bruce Booth acquired 545,454 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average cost of $5.50 per share, for a total transaction of $2,999,997.00. The disclosure for this purchase can be found here. Company insiders own 44.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/02/17/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-miragen-therapeutics-mgen-share-price.html.

Miragen Therapeutics Company Profile

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Insider Buying and Selling by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.